Lung Transplant Patients in the UK Fare Better Than Publicly Insured Americans - 3/24/15

Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than both publicly insured patients in the United Kingdom and privately insured Americans, according to the results of a study conducted by researchers from Johns Hopkins in Baltimore and U.K. colleagues working in that nation’s government-funded National Health Service.
Source: Johns Hopkins Medicine News - Category: Research Source Type: news

Related Links:

We describe the use of a decontamination protocol that allowed for successful lung transplantation in a cystic fibrosis patient with necrotizing pneumonia from highly antibiotic-resistant pathogens (Burkholderia and psuedomonas species). This strategy may allow for successful lung transplantation in cystic fibrosis patients with multi-drug resistant infections previously considered non-transplantable.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Abstract Cystic fibrosis (CF) is the most common life-limiting genetic disease in Caucasian patients. Continued advances have led to improved survival, and adults with CF now outnumber children. As our understanding of the disease improves, new therapies have emerged that improve the basic defect, enabling patient-specific treatment and improved outcomes. However, recurrent exacerbations continue to lead to morbidity and mortality, and new pathogens have been identified that may lead to worse outcomes. In addition, new complications, such as CF-related diabetes and increased risk of gastrointestinal cancers, are c...
Source: Annual Review of Medicine - Category: General Medicine Authors: Tags: Annu Rev Med Source Type: research
Background The aim of this study was to compare the pharmacokinetic profile, tolerability, and safety of a novel once-daily extended-release formulation of tacrolimus (LCPT) with that of once-daily prolonged-release tacrolimus (ODT) in stable adult lung transplant (LT) recipients. Methods Phase II, open-label, single-arm, single-center, prospective pilot pharmacokinetic study. Study population comprised 20 stable LT recipients receiving ODT, mean age 55.9 years (range, 38-67 years), 13 (65%) men. Patients were switched to LCPT in a 1:0.7 (mg/mg) conversion dose. Follow-up was 6 months, and cystic fibrosis patients wer...
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—General Source Type: research
Chronic airway inflammation and infection drive morbidity and mortality among patients with cystic fibrosis (CF). While Haemophilus influenzae and Staphylococcus aureus predominate in children, the prevalence of Pseudomonas aeruginosa increases as patients age. Other bacteria, including species within the Burkholderia cepacia complex (Bcc), are also more prevalent among adults with CF. Species within the Bcc accelerate lung function decline and can trigger development of “cepacia syndrome,” both before and after lung transplantation.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research
Authors: Li SS, Tumin D, Krone KA, Boyer D, Kirkby SE, Mansour HM, Hayes D Abstract INTRODUCTION: Survival after lung transplantation lags behind outcomes of other solid organ transplants and complications from lung transplant are the second most common cause of death in cystic fibrosis. Evolving surgical techniques, therapeutics and perioperative management have improved short-term survival after lung transplantation, yet have not translated into significant improvement in long-term mortality. Areas covered: We review risk factors for poor long-term outcomes among patients with cystic fibrosis undergoing lung tran...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
AbstractLung transplantation can offer life-prolonging therapy to children with otherwise terminal end-stage lung disease. However, infectious complications, like those experienced by their adult counterparts, are a significant cause of morbidity and mortality. These include bacteria, viruses, and fungi that infect the patient pretransplant and those that may be acquired from the donor or by the recipient in the months to years posttransplant. An understanding of the approach to the management of each potential infecting organism is required to ensure optimal outcomes. In particular, emphasis on aggressive preoperative man...
Source: Pediatric Drugs - Category: Pediatrics Source Type: research
Abstract Lung transplantation can offer life-prolonging therapy to children with otherwise terminal end-stage lung disease. However, infectious complications, like those experienced by their adult counterparts, are a significant cause of morbidity and mortality. These include bacteria, viruses, and fungi that infect the patient pretransplant and those that may be acquired from the donor or by the recipient in the months to years posttransplant. An understanding of the approach to the management of each potential infecting organism is required to ensure optimal outcomes. In particular, emphasis on aggressive preope...
Source: Paediatric Drugs - Category: Pediatrics Authors: Tags: Paediatr Drugs Source Type: research
Cystic fibrosis did not define Claire Wineland. She did.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
Claire Wineland, who has cystic fibrosis, needed a double-lung transplant to save her life. But she had a stroke and is now in a medically induced coma.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
Chronic Lung Allograft Dysfunction (CLAD) is the main cause of morbidity and mortality after the first year following lung transplantation (LTx). Risk factors of CLAD have been extensively studied, but the ass...
Source: BMC Microbiology - Category: Microbiology Authors: Tags: Research article Source Type: research
More News: Cystic Fibrosis | Government | Health | Insurance | Lung Transplant | National Health Service (NHS) | Research | Study | Transplant Surgery | Transplants | UK Health